Sharp tomosynthesis technology may catch breast cancer earlier

A technology that provides three-dimensional (3D) imaging of the breast may represent the next generation in breast cancer detection.

Similar to computed tomography, tomosynthesis acquires multiple, low-dose images at different angles. The images are then used to produce a series of 1-mm-thick slices that can be viewed as a 3D reconstruction of the breast. Features that might be obscured in a traditional two-dimensional mammogram due to overlapping breast anatomy that may mimic or mask a tumor can be easily identified and characterized in the tomosynthesis-produced images. This can reduce the number of false-positive or false-negative findings.

The tomosynthesis unit resembles earlier mammography machines, and the amount of breast compression required is identical to that required for conventional mammography.

University Hospitals (UH) Case Medical Center (Cleveland, Ohio) was involved with early studies of the tomosynthesis technology, and has announced that its patients are among the first in the nation to be offered the system.

“This revolutionary new technology provides exceptionally sharp images and is an important new tool in our arsenal to detect breast cancer early, when it is treatable,” explained Donna Plecha, MD, director of breast imaging at the medical center, in a statement issued by UH Case Medical Center.

close

Next Article in Web Exclusives

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Relapse of diffuse large B-cell lymphoma not detected by imaging scans

Imaging scans following treatment for diffuse large B-cell lymphoma do little to help detect a relapse, according to a new study. The overwhelming majority of patients with this aggressive lymphoma already have symptoms, an abnormal physical examination or an abnormal blood test at the time ...

Late recurrence risk in breast cancer differentiated by gene expression test

Patients at higher or lower risk for having their cancer recur elsewhere in the body more than 5 years after diagnosis can be differentiated by a gene expression test. The test measures the expression levels of 58 genes in estrogen receptor-positive breast cancers. These research ...

Locally advanced pancreatic cancer responds to FOLFIRINOX

FOLFIRINOX chemotherapy plus chemoradiation helped make resection possible in locally advanced pancreatic cancer.